Participating in open and frank conversations can be a catalyst for both positive change and a better industry. As we share our perspective you will find:
- Relevant and timely industry information
- Medication trends, and their impact
- Case studies, and the results of their related projects
- Special-subject on-demand webinars
Articles, blogs and podcasts
Sharing information with the industry is an important part of our mission. Our subject matter experts translate today’s news into comprehensive informational pieces to help you better understand the impact of a recent industry update, trend, or issue.
|
June 09, 2021 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more... |
|
May 26, 2021 · Public Policy & Regulatory Affairs Team
What does the beach have in common with topical medications in workers’ comp and auto no-fault? The Policy Guys and their special guest connect the two as they put a spotlight on topical medications – the specifics of what they are and why they may not always be medically necessary. Read more... |
|
May 25, 2021 · Public Policy & Regulatory Affairs Team
On May 24, 2021 the New York Workers’ Compensation Board (WCB) announced a delay of OnBoard-Limited Release via bulletin 046-1408. Read more... |
|
|
May 18, 2021 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more... |
|
May 12, 2021 · Optum Workers' Comp and Auto No-fault
Pain management takes more than a pill. To heal an injury at the root of pain, patients need to exercise the affected joint, muscle or tissue. Regaining strength, endurance and range of motion all make movement easier and less painful. A combined pharmacological and physical medicine approach is often the best way to help injured workers control and overcome pain. Read more... |
|
May 12, 2021 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved a higher-dose naloxone hydrochloride nasal spray – Kloxxado™ (8 mg) – on April 30, 2021. Naloxone is indicated for the emergency treatment of known or suspected opioid analgesic overdose, as manifested by respiratory and/or central nervous system (CNS) depression, for adults and pediatric patients. Read more... |
Page 1 of 17
Subscribe today to receive our latest blogs, articles, podcasts and more.
Additional Resources
Case Studies
Industry Trends Report
Continuing Education
